Picture loading failed.

Anti-ERBB3 therapeutic antibody (Pre-made Duligotuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Duligotuzumab (INN) is a humanized IgG1 monoclonal antibody designed for the treatment of cancer. It acts as an immunomodulator and binds to HER3.[1] It is in development by Roche. Clinical development for head and neck cancer and colorectal cancer have been discontinued, but phase I trials in combination with cobimetinib are evaluating safety for treatment of solid tumors.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-157-1mg 1mg 3090
GMP-Bios-ab-157-10mg 10mg 21890
GMP-Bios-ab-157-100mg 100mg 148000
GMP-Bios-ab-157-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-ERBB3 therapeutic antibody (Pre-made Duligotuzumab biosimilar,Whole mAb)
INN Name Duligotuzumab
TargetERBB3
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI Structure3p0v:HL:IM/3p0y:HL/3p11:HL
Year Proposed2012
Year Recommended2014
CompaniesGenentech;Roche
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedSolid tumours;Colorectal cancer;Head and neck cancer
Development Techna